
GlycoMimetics GLYC
Annual report 2025
added 02-26-2026
GlycoMimetics Total Current Liabilities 2011-2026 | GLYC
Annual Total Current Liabilities GlycoMimetics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 36.1 M | 9.61 M | 6.84 M | 8.88 M | 11.8 M | 12.4 M | 11 M | 8.76 M | 8.17 M | 6.33 M | 7.75 M | 6.46 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 36.1 M | 6.33 M | 11.2 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Amgen
AMGN
|
25.5 B | $ 349.36 | 2.75 % | $ 188 B | ||
|
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | ||
|
Amneal Pharmaceuticals
AMRX
|
882 M | $ 12.67 | 2.82 % | $ 3.97 B | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Arcutis Biotherapeutics
ARQT
|
130 M | $ 24.45 | 5.07 % | $ 3.11 B | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.47 | 8.17 % | $ 391 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
CymaBay Therapeutics
CBAY
|
36.8 M | - | - | $ 3.45 B | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
Aytu BioScience
AYTU
|
63.1 M | $ 2.72 | 5.84 % | $ 17.1 M | ||
|
Avid Bioservices
CDMO
|
70.6 M | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
49.6 M | - | - | $ 1.41 B | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Cabaletta Bio
CABA
|
50.2 M | $ 3.07 | - | $ 308 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.05 M | $ 3.08 | 1.65 % | $ 6.7 B | ||
|
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | ||
|
Cerus Corporation
CERS
|
101 M | $ 1.93 | 4.89 % | $ 368 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | ||
|
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | ||
|
Concert Pharmaceuticals
CNCE
|
16.1 M | - | - | $ 401 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
CTI BioPharma Corp.
CTIC
|
81.1 M | - | - | $ 1.2 B | ||
|
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1.33 M | - | -4.36 % | $ 27 M | ||
|
Cellectar Biosciences
CLRB
|
4.75 M | $ 2.82 | 2.55 % | $ 7.36 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
100 M | - | - | $ 2.18 B | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Dynavax Technologies Corporation
DVAX
|
78.6 M | - | - | $ 2.02 B | ||
|
Cyclerion Therapeutics
CYCN
|
725 K | $ 3.47 | -0.29 % | $ 8.74 M |